CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 18, 2020

Primary Completion Date

June 30, 2026

Study Completion Date

June 1, 2028

Conditions
Non Hodgkin Lymphoma (NHL)Mantle Cell Lymphoma (MCL)Chronic Lymphocytic Leukemia (CLL)Follicular LymphomaMarginal Zone LymphomaDiffuse Large B Cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Central Nervous System Lymphoma
Interventions
BIOLOGICAL

8/12-Day Production of Car-T Cells

A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.

BIOLOGICAL

8/12-Day Production of Cryopreserved Car-T Cells

A fixed cryopreserved dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.

BIOLOGICAL

12-Day Production of Car-T Cells

A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.

Trial Locations (1)

53226

RECRUITING

Medical College of Wisconsin and Froedtert Hospital, Milwaukee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER